genentech up $11 billion

An interesting note in a Huntley daily update caught my attention today.

The note went roughly as follows:-

Shares in Genentech jumped 24.8%. This was after an analysis of a Phase III trial showed the company's Avastin treatment plus chemotherapy extended the survival of patients with certain lung cancers. The advance added roughly $11 billion to the value of investors' holdings in the stock.

Genentech is a very big company, but an $11 billion jump in capitilisation is just breathtaking.

Poor old Solbec is sitting at roughly $22 million in capitalisation (excluding options), just simply no comparison.

I would love (just dreaming) to see Solbec rise by even 1% of the rise that Genentech (that would be a five fold jump in sp).